Search 
Thursday, August 28, 2014 ..:: Protocols » CTN Protocol ::.. Register  Login
 Clinical Trials Network Protocol Listing Minimize

Below is a listing of protocols available to Network members. CTN members may request any of the protocols below by completing a study request form. Some protocols may already have active CTN members participating in the study. All participating centers are posted in the right column.

For CTN members or other institutions with an active confidentiality disclosure agreement in place, you may see a table below for protocols in development that are available to investigators to assess their interest in the trial. If you do not see this table, you may contact the Network office to request access.

All Protocol documents are available for viewing by clicking on the protocol hyperlinks. If you are a CTN Member listed on your institution's Delegation of Authority or a multicenter authorized user, you will have access to the the full protocol documents.  If wish to gain access to particular trial, please contact the Network office at hcc-ctn@musc.edu or 843-792-1753. Thank you!


 Print   
 Protocols Available for CTN Activation and Enrollment Minimize

http://www.hollingscancercenter.org/network/Protocols/CTNProtocol/101838/tabid/251/Default.aspxlast updated February 4, 2013


>

Disease Site

CTO

Protocol Title

Participating Centers

HN
100949
Multicenter Randomized Phase II Study of Erlotinib Cisplatin and Radiotherapy versus Cisplatin and Radiotherapy in Patients with Stage III and IV Squamous Cell Carcinoma of the Head and Neck
Hollings Cancer Center
McLeod Regional Medical Center (study closed)
Spartanburg Regional Healthcare System (study closed)
(closed to accrual)
GI
101282
A Randomized Open-Label Multi-Institution Phase II Study of the Combination of Bevacizimab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma
Hollings Cancer Center
University of Southern California
Tennessee Oncology
University of Virginia

Columbia University Medical Center

California Pacific Medical Center

BMT

101669

Phase 1/2a Study Carfilzomib High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Hollings Cancer Center

Memorial Sloan-Kettering Cancer Center
UC San Diego  Moores Cancer Center (pending)

Medical College of Wisconsin (pending)

City of Hope (pending)

Fred Hutchinson Cancer Research Center (pending)
Sarcoma
101644
A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) with Pazopanib (P) or Gemcitabine (G) with Docetaxel (T) in Previously Treated Subjects with Advanced Soft Tissue Sarcoma
Hollings Cancer Center

Johns Hopkins University
MD Anderson

Sarcoma Oncology Center 

University of Colorado - Denver

University of Maryland
University of Michigan

Emory University (pending)

University of Iowa (pending)

Washington University - St. Louis (pending)

GI

101678

Phase II/III, Multi-center, Randomized Controlled Study to Compare the Efficacy and Safety of Gemcitabine Alone vs. ON 01910.Na Combined with Gemcitabine in Patients with Previously Untreated Metastatic Pancreatic Cancer

Hollings Cancer Center
McLeod Regional Medical Center (closed)

GI

101778

A Feasibility and Safety Study of Vaccination with Poly-ICLC and Dendritic Cells in Patients with Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma

Hollings Cancer Center

BMT

101801

Ancillary studies for a phase I/II clinical trial: mechanisms for enhanced platelet recovery with plerixafor treatment in myeloablative allogeneic hematopoietic stem cell transplantation

Hollings Cancer Center

Breast

101813

Vitamin D3 (Vit D3) Supplementation and T cell Immunomodulation in Patients with Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-III

Hollings Cancer Center

GU

101814

EXOSOME-DERIVED BIOMARKERS FOR THE DIAGNOSIS AND MANAGEMENT OF PROSTATE CANCER (PCa)

Hollings Cancer Center
GI
101822
Phase II study of Neoadjuvant Folfirinox Chemotherapy Followed by Capecitabine with Concurrent Limited Field Radiation Therapy in Patients with Localized Pancreatic Head Adenocarcinoma

Hollings Cancer Center

GI

101826

Pilot Study of Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery for Patients with Localized, Resectable Adenocarcinoma of the Pancreas

Hollings Cancer Center
Cutaneous

101838

A Feasibility and Safety Study of Vaccination with Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients with Metastatic and/or Unresectable Melanoma

Hollings Cancer Center

All Programs

101839

Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients with Advanced Cancer.

Hollings Cancer Center

GU

101681

 A Phase I Study of Docetaxel Plus Synthetic Lycopene in Metastatic Castration-Resistant, Chemotherapy-Naive Prostate Cancer in Patients with Biochemical or Clinical Relapse

 

Hollings Cancer Center

Ralph H. Johnson VA

 Print   
 Protocols Closed to Enrollment Minimize

Below are protocols that are closed to enrollment.

Date of Closure
CTO
Protocol Title
2009
100918
Phase II Study of Neoadjuvant Gemcitabine, Oxaliplatin and Cetuximab followed by Surgery or Concurrent External Beam Radiation with Capecitabine for Patients with Locally Advanced Unresectable Non-Metastatic Pancreatic Cancer
2012
100892
A Phase II Study of Neo-adjuvant Cisplatin, Gemcitabine, & Avastin, followed by Radical Cystectomy for Patients with Muscle Invasive, Resectable, Non-Metastatic Transitional Cell carcinoma (TCC) of the Bladder
2012
101466
A Phase I Trial of Preoperative Carboplatin or Cisplatin and Pemetrexed with Thoracic Radiation Therapy Followed by Lobectomy in Resectable Stage III Patients with Non Small Cell Lung Cancer
2012
101596
Molecular Effects of Afatinib: A Window of Opportunity Trial in Early Stage NSCLC
2013
101376
A phase II Trial of Intracycle Sequential Ofatumumab and Lenalidomide for the treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab
2013
101498
A Feasibility and Safety Study of Vaccination with Poly-ICLC and Peptide Pulsed Dendritic Cells in Patients with Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma.
2013
101637
Phase Ib/IIA Study of Cabazitaxel plus Bavituximab for Patients with Castration-Resistant Prostate Cancer Previously Treated with Chemotherapy


 Print   
Copyright 2008 by Hollings Cancer Center   Terms Of Use  Privacy Statement